Le Lézard
Classified in: Health
Subject: SVY

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028


NEW YORK, Jan. 24, 2020 /PRNewswire/ --

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

Summary

Read the full report: https://www.reportlinker.com/p05842037/?utm_source=PRN

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms.The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017).

Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

Epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast.The disease definition for COPD was based on symptoms and the results of spirometry testing.

The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. Epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope
- The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ?35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
- The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
- Understand magnitude of COPD population by severity at diagnosis.

Read the full report: https://www.reportlinker.com/p05842037/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 09:13
CareSignal, offering Deviceless Remote Patient Monitoring validated by over 10 peer-reviewed journals to deliver an industry-leading clinical and financial return, announces the launch of CareSignal AI to address one of the most pressing areas in...

at 09:10
US Oncology Research, one of the largest community-based oncology research site management organizations in the U.S., is celebrating the significant milestone of contributing to the FDA approval of over 100 cancer therapies. This achievement is a...

at 09:10
OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, today announced the OH02A1S?the world's first RGB-IR medical image sensor, which provides simultaneous white-light RGB captures and infrared monochrome captures...

at 09:10
IgGenix, Inc, today congratulated co-founder Kari Nadeau, M.D., Ph.D., and her co-author, Sloan Barnett, on the publication of their book ?The End of Food Allergy', a seminal work detailing the prevention, diagnosis and reversal of food allergies,...

at 09:10
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") today announced financial results for its fiscal year 2021 first quarter ended July 31, 2020. Q1 Fiscal 2021 Financial Highlights:  Revenue increases by $1.1 million, or 39%, to $3.8 million...

at 09:09
In honor of Prostate Cancer Awareness Month, the Depend brand announced today its partnership with Major League Baseball (MLB) All-Star Mark Teixeira and the Prostate Cancer Foundation (PCF) for the Stand Strong for Men's Healthtm campaign, an...



News published on 24 january 2020 at 08:00 and distributed by: